TrialBMC infectious diseases2013

Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.

Dorothee Kieninger et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.